Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Siglec15 is a membrane-bound lectin and an immunosuppressive transmembrane protein that functions as an inhibitory immune checkpoint. It plays a crucial role in regulating inflammatory processes, promoting cancer development by repressing T lymphocyte activation and proliferation, and facilitating tumor cell immune escape. Siglec15 is also implicated in osteoclast differentiation and bone remodeling. Its expression is often upregulated in various cancer types and is associated with an immunosuppressive tumor microenvironment, making it a significant target for novel immunotherapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Siglec15.